SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced completion of the validation study that it will use to support submission of an upcoming traditional 510(k) for the PLAC Test for Lp-PLA2 Activity. The PLAC Test for Lp-PLA2 Activity is an enzyme assay for the quantitative determination of Lp-PLA2 (lipoprotein-associated phospholipase A2) activity in human plasma and serum. diaDexus anticipates submitting the 510(k) to the Food and Drug Administration (FDA) by mid-year 2014.
Help employers find you! Check out all the jobs and post your resume.
